宫颈癌在全球女性恶性肿瘤中排列第四位,严重威胁女性健康。高危型HPV持续感染是导致宫颈癌的主要原因,预防性HPV疫苗可以减少宫颈癌的发生,但无法治疗已经感染或病变的组织,治疗性HPV疫苗的研发目前是研究热点。 Cervical cancer is the fourth malignant tumor of women in the world, which seriously threatens women’s health. The persistent infection of high-risk HPV is the main cause of cervical cancer. Prophylactic HPV vaccine can reduce the occurrence of cervical cancer, but cannot treat the tissues that have been infected or diseased. The research and development of therapeutic HPV vaccine is currently a research hotspot.
人乳头瘤病毒,疫苗,预防性疫苗,治疗性疫苗, Human Papillomavirus
Vaccine
Prophylactic Vaccine
Therapeutic Vaccine
人乳头瘤病毒(HPV)疫苗的研究进展<sup> </sup>
胡 彬,柳 露,潘慧敏,张旭梅. 人乳头瘤病毒(HPV)疫苗的研究进展Research Progress of Human Papillomavirus Vaccine[J]. 临床医学进展, 2019, 09(08): 1013-1017. https://doi.org/10.12677/ACM.2019.98154
参考文献References
McGuire, S. (2016) World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015. Advances in Nutrition: An International Review Journal, 7, 418-419.
https://doi.org/10.3945/an.116.012211
Chen, W., et al. (2016) Cancer Statistics in China, 2015. CA: A Cancer Journal for Clinicians, 66, 115-132.
https://doi.org/10.3322/caac.21338
de Villiers, E.M., Fauquet, C., Broker, T.R., Bernard, H.-U. and Hausen, H. (2004) Classification of Papillomaviruses. Virology, 324, 17-27.
https://doi.org/10.1016/j.virol.2004.03.033
Satterwhite, C.L., et al. (2013) Sexually Transmitted Infections among US Women and Men: Prevalence and Incidence Estimates, 2008. Sexually Transmitted Diseases, 40, 187-193.
Myers, E.R., McCrory, D.C., Nanda, K., Bastian, L. and Matchar, D.B. (2000) Mathematical Model for the Natural History of Human Papillomavirus Infection and Cervical Carcinogenesis. American Journal of Epidemiology, 151, 1158-1171.
Muñoz, N., et al. (2003) Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer. The New England Journal of Medicine, 348, 518-527.
Dürst, M., Gissmann, L., Ikenberg, H. and zur Hausen, H. (1983) A Papillomavirus DNA from a Cervical Carcinoma and Its Prevalence in Cancer Biopsy Samples from Different Geographic Regions. Proceedings of the National Academy of Sciences of the United States of America, 80, 3812-3815.
Hartwig, S., St Guily, J.L., Dominiak-Felden, G., Alemany, L. and de Sanjosé S. (2017) Estimation of the Overall Burden of Cancers, Precancerous Lesions, and Genital Warts Attributable to 9-Valent HPV Vaccine Types in Women and Men in Europe. Infectious Agents and Cancer, 12, 19.
de Martel, C., Plummer, M., Vignat, J. and Franceschi, S. (2017) Worldwide Burden of Cancer Attributable to HPV by Site, Country and HPV Type. International Journal of Cancer, 141, 664-670.
https://doi.org/10.1002/ijc.30716
Chen, W., et al. (2009) Human Papillomavirus Type-Distribution in Cervical Cancer in China: The Importance of HPV 16 and 18. Cancer Causes & Control, 20, 1705-1713.
Chen, W., et al. (2016) The Variable Clinicopathological Categories and Role of Human Papillomavirus in Cervical Adenocarcinoma: A Hospital Based Nation-Wide Multi-Center Retrospective Study across China. International Journal of Cancer, 139, 2687-2697.
Mesri, E.A., Feitelson, M.A. and Munger, K. (2014) Human Viral Oncogenesis: A Cancer Hallmarks Analysis. Cell Host & Microbe, 15, 266-282.
余艳琴, 乔友林. 中国HPV预防性疫苗防治宫颈癌的应用前景[J]. 肿瘤预防与治疗, 2018, 31(4): 237-241.
Committee on Practice Bulletins—Gynecology (2012) ACOG Practice Bulletin Number 131: Screening for Cervical Cancer. Obstetrics and Gynecology, 120, 1222-1238.
Stanley, M., Lowy, D.R. and Frazer, I. (2006) Chapter 12: Prophylactic HPV Vaccines: Underlying Mechanisms. Vaccine, 24, S106-S113.
https://doi.org/10.1016/j.vaccine.2006.05.110
Van Damme, P., et al. (2016) A Phase III Clinical Study to Compare the Immunogenicity and Safety of the 9-Valent and Quadrivalent HPV Vaccines in Men. Vaccine, 34, 4205-4212.
https://doi.org/10.1016/j.vaccine.2016.06.056
Hancock, G., Hellner, K. and Dorrell, L. (2017) Therapeutic HPV Vaccines. Best Practice & Research Clinical Obstetrics & Gynaecology, 47, 59-72.
https://doi.org/10.1016/j.bpobgyn.2017.09.008
Schiller, J.T., Castellsagué, X. and Garland, S.M. (2012) A Review of Clinical Trials of Human Papillomavirus Prophylactic Vaccines. Vaccine, 30, F123-F138.
https://doi.org/10.1016/j.vaccine.2012.04.108
Emiko, P., et al. (2015) Use of 9-Valent Human Papillomavirus (HPV) Vaccine: Updated HPV Vaccination Recommendations of the Advisory Committee on immunization Practices. Mmwr Morbidity & Mortality Weekly Report, 64, 300-304.
Pitisuttithum, P., Velicer, C. and Luxembourg, A. (2015) 9-Valent HPV Vaccine for Cancers, Pre-Cancers and Genital Warts Related to HPV. Expert Review of Vaccines, 14, 1405-1419.
https://doi.org/10.1586/14760584.2015.1089174
Cuschieri, K., et al. (2015) Influence of HPV Type on Prognosis in Patients Diagnosed with Invasive Cervical Cancer. International Journal of Cancer, 135, 2721-2726.
https://doi.org/10.1002/ijc.28902
罗雅娟, 王丹丹, 杨清. HPV致女性生殖道疾病及HPV疫苗现况[J]. 国际生殖健康/计划生育杂志, 2019, 38(3): 244-248.
Han, J.J., Beltran, T.H., Song, J.W., Klaric, J. and Choi, Y.S. (2017) Prevalence of Genital Human Papillomavirus Infection and Human Papillomavirus Vaccination Rates among US Adult Men: National Health and Nutrition Examination Survey (NHANES) 2013-2014. JAMA Oncology, 3, 810-816.
Lu, P.J., et al. (2019) Association of Provider Recommendation and Human Papillomavirus Vaccination Initiation among Male Adolescents Aged 13-17 Years-United States. The Journal of Pediatrics, 206, 33-41.e1.